Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services’s Arcutis Biotherapeutics ARQT Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$363K	Sell	15,352 -1,080	-7%	-$27.6K	﹤0.01%	2600
2025 Q4	$480K	Buy	16,432 +2,221	+16%	+$56.9K	﹤0.01%	2510
2025 Q3	$292K	Sell	14,211 -1,455	-9%	-$22.9K	﹤0.01%	2822
2025 Q2	$217K	Buy	+15,666	New	+$220K	﹤0.01%	2920
2025 Q1	–	Sell	-20,912	Closed	-$291K	–	2987
2024 Q4	$291K	Buy	+20,912	New	+$229K	﹤0.01%	2409
2024 Q1	–	Sell	-20,000	Closed	-$64.6K	–	2488
2023 Q4	$64.6K	Buy	20,000 +10,000	+100%	+$27.2K	﹤0.01%	2200
2023 Q3	$53.1K	Buy	+10,000	New	+$85K	﹤0.01%	2158

Other funds holding ARQT

Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return

Jennison Associates

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return